Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H2 2018

  • ID: 4590328
  • Report
  • 106 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Celldex Therapeutics Inc
  • Etubics Corp
  • GlaxoSmithKline Plc
  • Imugene Ltd
  • Merus NV
  • MORE
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H2 2018

Summary:

According to the recently published report 'Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2018'; Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) pipeline Target constitutes close to 25 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes.

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Receptor tyrosine-protein kinase erbB-3 or HER3 is a membrane bound protein encoded by the ERBB3 gene. It belongs to tyrosine-protein kinase family. It plays an essential role as cell surface receptor for neuregulins. It binds to neuregulin-1 (NRG1) and is activated by it. It also activated by CSPG5.

The report 'Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2018' outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 8, 5, 1, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Breast Cancer, Solid Tumor, Esophageal Cancer, Head And Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Lung Adenocarcinoma, Metastatic Colorectal Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Biliary Tumor, Carcinomas, Colorectal Tumor, Epithelial Tumor, Gallbladder Cancer, Gastroesophageal (GE) Junction Carcinomas, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Malignant Mesothelioma, Metastatic Hepatocellular Carcinoma (HCC), Nasopharyngeal Cancer, Neuroendocrine Tumors, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Osteosarcoma, Pancreatic Tumor, Paranasal Sinus And Nasal Cavity Cancer, Peritoneal Tumor, Sarcomas, Skin Cancer, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Thyroid Cancer and Transitional Cell Cancer (Urothelial Cell Cancer).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)
  • The report reviews Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Celldex Therapeutics Inc
  • Etubics Corp
  • GlaxoSmithKline Plc
  • Imugene Ltd
  • Merus NV
  • MORE
Introduction

Report Coverage

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Overview

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Celldex Therapeutics Inc

Daiichi Sankyo Co Ltd

Etubics Corp

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Hanmi Pharmaceuticals Co Ltd

Hummingbird Bioscience Pte Ltd

ImmunoGen Inc

Imugene Ltd

MediaPharma SRL

Merrimack Pharmaceuticals Inc

Merus NV

Novartis AG

Symphogen A/S

Taiho Pharmaceutical Co Ltd

Takis Srl

XuanZhu Pharma Co Ltd

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Drug Profiles

AV-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibodies to Inhibit EGFR and ERBB3 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDX-3379 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elgemtumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETBX-031 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FCN-411 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2849330 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMBD-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

huHER3-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-5209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lumretuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MCLA-125 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MPEV-201959 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide to Inhibit EGFR, ERBB2 and ERBB3 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

patritumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poziotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sapitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seribantumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit EGFR, HER2 and HER3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sym-013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-0728 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TK-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target HER1, HER2, HER3 and IGF1R for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target HER3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XZP-5491 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Dormant Products

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Discontinued Products

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Product Development Milestones

Featured News & Press Releases

May 29, 2018 : Merrimack to Present Data on Seribantumab at ASCO 2018 Annual Meeting

Apr 23, 2018 : Spectrum Pharmaceuticals Announces Publication of Poziotinib Data in Nature Medicine

Apr 20, 2018 : Celldex Therapeutics presents posters on CDX-3379 at the AACR Annual Meeting 2018

Apr 17, 2018 : Spectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in Chicago

Apr 10, 2018 : Spectrum Pharmaceuticals Announces Update of MD Anderson’s Phase 2 Data Studying Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer Patients

Mar 12, 2018 : Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer

Feb 26, 2018 : Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast Cancer

Dec 21, 2017: CANbridge Life Sciences Submits Investigational New Drug Application for CAN017 Trial in Esophageal Squamous Cell Cancer (ESCC) In China

Nov 17, 2017: Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma

Oct 30, 2017: Merrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung Cancer

Oct 30, 2017: Spectrum Pharmaceuticals Announces Initiation of a Multicenter Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer (NSCLC) Patients with Exon 20 Insertion Mutation in EGFR or HER

Oct 17, 2017: Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan

Sep 28, 2017: Spectrum Pharmaceuticals Highlights Poziotinib Data in Lung Cancer to be Presented in an Oral Presentation at the 18th IASLC World Conference on Lung Cancer in Yokohama, Japan, October 15-18,

Sep 13, 2017: AVEO Oncology Announces Receipt of $0.5 million Payment from CANbridge

Apr 03, 2017: AVEO Announces Milestone Payment from CANbridge for AV-

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1)

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Companies, H2 2018 (Contd..5), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by AstraZeneca Plc, H2 2018

Pipeline by AVEO Pharmaceuticals Inc, H2 2018

Pipeline by Celldex Therapeutics Inc, H2 2018

Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Pipeline by Etubics Corp, H2 2018

Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Pipeline by GlaxoSmithKline Plc, H2 2018

Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018

Pipeline by Hummingbird Bioscience Pte Ltd, H2 2018

Pipeline by ImmunoGen Inc, H2 2018

Pipeline by Imugene Ltd, H2 2018

Pipeline by MediaPharma SRL, H2 2018

Pipeline by Merrimack Pharmaceuticals Inc, H2 2018

Pipeline by Merus NV, H2 2018

Pipeline by Novartis AG, H2 2018

Pipeline by Symphogen A/S, H2 2018

Pipeline by Taiho Pharmaceutical Co Ltd, H2 2018

Pipeline by Takis Srl, H2 2018

Pipeline by XuanZhu Pharma Co Ltd, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Discontinued Products, H2 2018

Discontinued Products, H2 2018 (Contd..1), H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AstraZeneca Plc
  • AVEO Pharmaceuticals Inc
  • Celldex Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Etubics Corp
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Hanmi Pharmaceuticals Co Ltd
  • Hummingbird Bioscience Pte Ltd
  • ImmunoGen Inc
  • Imugene Ltd
  • MediaPharma SRL
  • Merrimack Pharmaceuticals Inc
  • Merus NV
  • Novartis AG
  • Symphogen A/S
  • Taiho Pharmaceutical Co Ltd
  • Takis Srl
  • XuanZhu Pharma Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll